These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 16079165

  • 1. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3.
    Sarzi-Puttini P, Atzeni F, Schölmerich J, Cutolo M, Straub RH.
    Ann Rheum Dis; 2006 Mar; 65(3):301-5. PubMed ID: 16079165
    [Abstract] [Full Text] [Related]

  • 2. Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol.
    Straub RH, Sarzi-Puttini P, Atzeni F, Buttgereit F, Carrabba M, Cutolo M.
    Ann Rheum Dis; 2005 Sep; 64(9):1353-6. PubMed ID: 15708882
    [Abstract] [Full Text] [Related]

  • 3. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
    Straub RH, Pongratz G, Schölmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM.
    Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
    [Abstract] [Full Text] [Related]

  • 4. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
    Straub RH, Härle P, Atzeni F, Weidler C, Cutolo M, Sarzi-Puttini P.
    J Rheumatol; 2005 Jul; 32(7):1253-8. PubMed ID: 15996060
    [Abstract] [Full Text] [Related]

  • 5. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P.
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 7. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.
    Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK.
    Scand J Rheumatol; 2007 Dec; 36(2):91-6. PubMed ID: 17476613
    [Abstract] [Full Text] [Related]

  • 8. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P.
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [Abstract] [Full Text] [Related]

  • 9. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

  • 10. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy.
    Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Säemann M, Schwarzinger I, Buranyi B, Steiner G, Smolen JS.
    Ann Rheum Dis; 2007 Oct; 66(10):1284-8. PubMed ID: 17293363
    [Abstract] [Full Text] [Related]

  • 11. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S, McColl G, Wicks IP.
    Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
    [Abstract] [Full Text] [Related]

  • 12. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [Abstract] [Full Text] [Related]

  • 13. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems.
    Härle P, Straub RH, Wiest R, Mayer A, Schölmerich J, Atzeni F, Carrabba M, Cutolo M, Sarzi-Puttini P.
    Ann Rheum Dis; 2006 Jan; 65(1):51-6. PubMed ID: 15941834
    [Abstract] [Full Text] [Related]

  • 14. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
    Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM.
    Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
    [Abstract] [Full Text] [Related]

  • 15. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM, Tak PP, Sarzi-Puttini P.
    Arthritis Rheum; 2008 Apr; 58(4):976-84. PubMed ID: 18383357
    [Abstract] [Full Text] [Related]

  • 16. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
    Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, Ertenli I, Dogan I, Calguneri M.
    J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
    [Abstract] [Full Text] [Related]

  • 17. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.
    Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW.
    Ann Rheum Dis; 2005 Aug; 64(8):1195-8. PubMed ID: 15731289
    [Abstract] [Full Text] [Related]

  • 18. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 19. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH, Bartelds GM, Vis M, van der Horst AR, Wolbink GJ, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Lems WF, Nurmohamed MT, Aarden L, Hamann D.
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [Abstract] [Full Text] [Related]

  • 20. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
    Popa C, Barrera P, Joosten LA, van Riel PL, Kullberg BJ, van der Meer JW, Netea MG.
    Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.